UNSPSC 51342713: Atazanavir sulfate

This classification denotes a protease inhibitor with the molecular formula C38H52N6O7.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4MT4VIE29P, chemically known as 2,5,6,10,13-pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3s,8s,9s,12s)-, sulfate (1:1) (salt) but more generally known as atazanavir sulfate, which bears US NIH Compound Identifier 158550.

UNSPSC 51342713 Atazanavir sulfate is a Commodity code for a specific antiretroviral pharmaceutical product. Recent state and local procurement activity under this code shows little relevant matching. The source records show two opportunities tagged to this code: one from the Illinois Department of Public Health procuring Doxycycline Hyclate and Ciprofloxacin Hydrochloride through a piggyback contract awarded to Chartwell Rx LLC, and another from Seminole County, Florida seeking Naloxone and drug deactivation systems. Neither opportunity involves atazanavir sulfate procurement directly; the Illinois award was completed in August 2026 for antibiotic pharmaceuticals, while the Seminole County solicitation, posted June 30, 2026, targets emergency-response pharmaceuticals and related equipment.

State and local governments soliciting under this code appear to pursue pharmaceutical acquisitions through cooperative purchasing vehicles and competitive IFB processes, with issuing bodies including state health departments and county public-health authorities. Geographic activity in the recent record spans Illinois and Florida, though the code shows minimal direct solicitation activity for atazanavir sulfate specifically. The Illinois Department of Public Health procurement through MMCAP Infuse represents a piggyback model awarding a $2,999,999.11 contract over three years including renewals; Seminole County's IFB for naloxone and deactivation systems (due July 26, 2023) required quarterly deliveries and included FEMA compliance provisions. Because the code nominally covers a single antiretroviral drug product but recent tagged opportunities procure unrelated pharmaceuticals, this code shows little active state and local demand for atazanavir sulfate or similar targeted acquisitions under this specific classification.